Eurofins Genomics Receives Accreditation from CLIA and CAP for New Laboratory in Louisville

News provided by

Dec 06, 2016, 12:12 ET

LOUISVILLE, Ky., Dec. 6, 2016 /PRNewswire/ -- Eurofins Genomics today announced it has received notice of accreditation from the College of American Pathologists (CAP) and certification under the Clinical Laboratory Improvement Amendments (CLIA) for its new laboratory in Louisville, KY, where the company recently moved its North American headquarters.

"Our new CLIA-licensed and CAP-accredited clinical laboratory offers Sanger sequencing -- which is still considered the 'Gold Standard' method for validation of many clinical molecular diagnostic tests and for confirmation of variants detected by other methods such as next generation sequencing," said Martin Kunz, President of Eurofins Genomics. "The new clinical laboratory gains the sequencing expertise already in place at Eurofins Genomics in Louisville, a world leader in fast, accurate Sanger sequencing, and will initially focus on Sanger sequencing services for other clinical laboratories that require sequencing performed in CLIA and CAP regulatory environments. Further, as we launch our new oligo synthesis service, customers developing NGS assays can benefit from a one-stop shop that offers cost savings and convenience in ordering both oligos and Sanger sequencing services for the development of clinical tests."

CAP accreditation is an internationally recognized standard of operational excellence. The U.S. federal government recognizes the CAP Laboratory Accreditation Program, begun in the early 1960s, as being equal to or more stringent than the government's own inspection program. During the CAP accreditation process, designed to ensure the highest standard of care for all patients, inspectors examine the laboratory's records and quality control of procedures. CAP inspectors also examine laboratory staff qualifications, equipment, facilities, safety program and record, and overall management.

CLIA regulations include federal standards applicable to all U.S. facilities or sites that test human specimens for health assessment or to diagnose, prevent, or treat disease. To gain CLIA certification, Eurofins Genomics had to demonstrate quality standards for proficiency testing, patient test management, quality control, personnel qualifications, and quality assurance.

More information is available at www.eurofinsgenomics.com.

About the College of American Pathologists

The College of American Pathologists (CAP), celebrating 50 years as the gold standard in laboratory accreditation, is a medical society that serves more than 18,000 physician members and the global laboratory community. It is the world's largest association composed exclusively of board-certified pathologists and is the worldwide leader in laboratory quality assurance. The College advocates accountable, high-quality, and cost-effective patient care. More information about the CAP can be found at www.cap.org.

About Eurofins Genomics

Eurofins Genomics company is an international provider of DNA sequencing services, genotyping services, DNA synthesis products, and bioinformatics services for pharma, diagnostics, food, agriculture, biotechnological, and research markets. Eurofins Genomics operates leading R&D and production sites in the USA, Canada, Germany, India, and Japan.

Eurofins Genomics is the genomic services brand of the Eurofins Group, the worldwide leader in food, environmental and pharmaceutical testing. With 25,000 staff in over 250 laboratories across 39 countries, Eurofins offers a portfolio of over 130,000 reliable analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group provides its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.

Contacts:

Media:

Nicole Litchfield
Bioscribe, Inc.
415-793-6468
[email protected]

Company:

James Corne
Eurofins Genomics
502-302-6351
[email protected]

SOURCE Eurofins Genomics